statistiche ricercatore

AGENO, WALTER

Distribuzione geografica

Continente	#
NA - Nord America	43.757
EU - Europa	22.712
AS - Asia	6.118
SA - Sud America	78
Continente sconosciuto - Info sul continente non disponibili	55
OC - Oceania	24
AF - Africa	16
Totale	72.760

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	43.696
IT - Italia	11.537
UA - Ucraina	4.067
TR - Turchia	2.785
SE - Svezia	1.797
DE - Germania	1.539
VN - Vietnam	1.398
IE - Irlanda	1.230
CN - Cina	1.188
FI - Finlandia	749
GB - Regno Unito	712
SG - Singapore	578
RU - Federazione Russa	568
FR - Francia	278
IN - India	66
BR - Brasile	54
CA - Canada	54
EU - Europa	53
BE - Belgio	43
NL - Olanda	42
JP - Giappone	39
CZ - Repubblica Ceca	33
AU - Australia	19
ES - Italia	18
CH - Svizzera	13
PT - Portogallo	13
PL - Polonia	11
CL - Cile	10
AT - Austria	9
RO - Romania	9
HK - Hong Kong	8
AR - Argentina	7
EG - Egitto	7
IR - Iran	7
MY - Malesia	7
TW - Taiwan	7
DK - Danimarca	6
IL - Israele	6
GR - Grecia	5
HU - Ungheria	5
MX - Messico	5
NZ - Nuova Zelanda	5
BG - Bulgaria	4
KR - Corea	4
LK - Sri Lanka	4
LT - Lituania	4
MK - Macedonia	4
CO - Colombia	3
IQ - Iraq	3
NG - Nigeria	3
AE - Emirati Arabi Uniti	2
AL - Albania	2
BD - Bangladesh	2
DZ - Algeria	2
EE - Estonia	2
HR - Croazia	2
ID - Indonesia	2
KW - Kuwait	2
KZ - Kazakistan	2
LI - Liechtenstein	2
NO - Norvegia	2
PE - Perù	2
SI - Slovenia	2
A1 - Anonimo	1
A2 - ???statistics.table.value.countryCode.A2???	1
AO - Angola	1
BA - Bosnia-Erzegovina	1
BO - Bolivia	1
BY - Bielorussia	1
CR - Costa Rica	1
EC - Ecuador	1
JO - Giordania	1
KE - Kenya	1
LA - Repubblica Popolare Democratica del Laos	1
MA - Marocco	1
MD - Moldavia	1
MM - Myanmar	1
PH - Filippine	1
PK - Pakistan	1
PR - Porto Rico	1
QA - Qatar	1
RS - Serbia	1
SA - Arabia Saudita	1
TH - Thailandia	1
TN - Tunisia	1
Totale	72.760

Salva come PNG Salva come JPEG

Città	#
Milan	8.480
Fairfield	7.198
Woodbridge	4.799
Houston	3.518
Ashburn	3.515
Jacksonville	3.301
Seattle	2.793
Wilmington	2.600
Cambridge	2.459
Ann Arbor	2.425
Chandler	2.236
Izmir	1.393
Princeton	1.350
Dublin	1.222
Dearborn	961
Boardman	807
Dong Ket	683
Nyköping	664
Rome	620
Singapore	518
San Diego	398
San Mateo	308
Ogden	261
Chicago	218
Como	188
Beijing	168
Washington	164
London	145
Düsseldorf	137
Santa Clara	127
Hefei	125
Redmond	122
Nanjing	97
Kocaeli	88
New York	86
Kunming	81
Verona	80
Norwalk	75
Los Angeles	60
Guangzhou	59
Helsinki	59
Nanchang	57
Jinan	52
Munich	51
Dallas	45
Kilburn	39
Falls Church	38
Brussels	36
Besana In Brianza	33
Frankfurt am Main	33
Tokyo	32
Fuzhou	30
Philadelphia	30
Brno	28
Toronto	28
Prescot	27
Redwood City	26
Chiswick	25
Zhengzhou	25
Berlin	23
Shenyang	22
Acton	20
New Bedfont	20
Shanghai	20
Phoenix	19
Ponte Lambro	19
Detroit	18
São Paulo	18
Wandsworth	18
Hounslow	17
Wuhan	16
Changsha	15
Pune	15
Xian	15
Chengdu	14
Islington	14
Southwark	14
Chongqing	13
Indiana	13
Lappeenranta	13
San Francisco	13
Auburn Hills	12
Hangzhou	12
Hebei	12
Andover	11
Bologna	11
Ningbo	11
Quzhou	11
Saint Petersburg	11
Shaoxing	11
Busto Arsizio	9
Paris	9
Stockholm	9
Suresnes	9
Bangalore	8
Baotou	8
Florence	8
Madrid	8
Ralingen	8
Varese	8
Totale	55.778

Salva come PNG Salva come JPEG

Nome	#
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes	265
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study	243
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis	238
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery	227
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature	227
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal	220
Risk of recurrence of unusual site venous thromboembolism	214
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment	205
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study	204
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review	201
Abdominal obesity and the risk of recurrent deep vein thrombosis	199
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients	198
Breadth of complications of long-term oral anticoagulant care	196
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry	194
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome	194
Management of recurrent venous thromboembolism in cancer patients	192
Optimal treatment duration of venous thrombosis	191
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio.	190
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry	188
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism	187
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial	186
Patient selection for thromboprophylaxis in medical inpatients	186
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis.	186
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study	186
Exaggerated initial response to warfarin following heart valve replacement	184
Prevention and treatment of venous thromboembolism	184
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study	181
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.	180
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable?	180
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review	180
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice	180
Venous ischemic syndromes	180
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature	179
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure”	179
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry.	178
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis	178
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data	177
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study	176
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients	175
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis	175
Warfarin interactions with antibiotics in the ambulatory care setting	174
Management of incidental splanchnic vein thrombosis in cancer patients	174
Treating patients with cancer and acute venous thromboembolism	173
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation	172
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications	171
Duration of anticoagulation after venous thromboembolism in real world clinical practice	170
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism	170
Managing challenging patients with venous thromboembolism: A practical, case-based approach	170
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study	170
Venous and arterial thrombosis in patients with HIV infection	169
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis	169
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy	169
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty	168
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients	168
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation	168
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study	168
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism	168
Update on the diagnosis and management of pulmonary embolism	168
Direct oral anticoagulants in rare venous thrombosis	167
When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH	165
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis	165
Oral rivaroxaban for symptomatic venous thromboembolism	164
Applying EBM in clinical practice	164
Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice.	164
ABO blood group and vascular disease: an update	164
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants	164
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature	164
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis	163
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE	163
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study	163
Management of primary care patients with suspected deep vein thrombosis: use of a therapeutic dose of low-molecular-weight heparin to avoid urgent ultrasonographic evaluation.	163
Statins and secondary prevention of ischemic and hemorrhagic stroke	162
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial	162
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature	162
Emergency reversal of anticoagulation with vitamin K antagonists with 3-factor prothrombin complex concentrates in patients with major bleeding	161
Spotlight on real-world evidence for the treatment of DVT: XALIA	161
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians	161
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study	160
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study	160
Guidance for the management of venous thrombosis in unusual sites	159
Venous thromboembolism: Past, present and future	159
Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for intracranial hemorrhage	158
Dabigatran in clinical practice: Contemporary overview of the evidence	158
Is diabetes a hypercoagulable state? A critical appraisal	158
Low-molecular -weight heparin in pregnancies after ART -A retrospective study-	158
Edoxaban in Atrial Fibrillation and Venous Thromboembolism—Ten Key Questions and Answers: A Practical Guide	158
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study	158
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree?	157
JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia.	157
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies	157
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study	157
Brain natriuretic peptide and preclinical chronic thromboembolic pulmonary hypertension.	156
Epidemiology and pathophysiology of venous thromboembolism: similarities with atherothrombosis and the role of inflammation	156
Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists	156
Intracranial bleeding risk after minor traumatic brain injury in patients on antithrombotic drugs	156
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature	155
Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis	155
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin?	155
Prevention of in-hospital VTE: why can't we do better?	154
In vitro effects of Apixaban on 5 different cancer cell lines	154
Totale	17.555

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	306.216
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	306.216

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	8.609	0	0	0	0	0	1.555	2.116	1.734	1.148	917	259	880
2020/2021	13.656	231	1.104	1.560	1.768	972	1.396	543	1.226	1.503	803	953	1.597
2021/2022	6.828	757	872	355	182	402	376	337	375	386	1.267	644	875
2022/2023	6.740	824	258	431	650	510	1.571	19	787	1.024	268	191	207
2023/2024	13.559	2.152	2.188	2.195	2.612	2.767	824	95	147	391	79	37	72
2024/2025	3.034	69	75	1.781	238	230	641	0	0	0	0	0	0
Totale													73.635